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Abstract
Leucine-rich repeat kinase 2 (LRRK2) is linked to Parkinson’s disease and may represent an
attractive therapeutic target. Here we report a 2,4-dianilino-5-chloro-pyrimidine, TAE684, a
previously reported inhibitor of anaplastic lymphoma kinase (ALK), is also a potent inhibitor of
LRRK2 kinase activity (IC50 of 7.8 nM against wild-type LRRK2, 6.1 nM against the G2019S
mutant). TAE684 substantially inhibits Ser910 and Ser935 phosphorylation of both wild-type
LRRK2 and G2019S mutant at a concentration of 0.1–0.3 µM in cells and in mouse spleen and
kidney, but not in brain, following oral doses of 10 mg/kg.
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Parkinson’s disease (PD) is a debilitating neurodegenerative disease that affects over one
million Americans.1,2 Recent genetic studies have revealed an underlying genetic cause in at
least 10% of all PD cases,3 which provides new opportunities for discovery of molecularly
targeted therapeutics that may ameliorate neurodegeneration. Among the genes associated
with PD, leucine-rich repeat kinase 2 (LRRK2) is unique because of a missense mutation,
G2019S, is frequently found in not only familial but also sporadic Parkinson’s disease
cases.4,5 The G2019S mutation enhances kinase activity, suggesting that small molecule
LRRK2 kinase inhibitors may be able to block aberrant LRRK2-dependent signaling in
Parkinson’s disease.6,7
LRRK2 kinase inhibitors are being actively pursued and recently first-generation ‘tool’
inhibitors that exhibit excellent potency and selectivity for LRRK2 such as LRRK2-IN-18
and CZC-251469 have been reported. However, neither compound is able to achieve good
exposure in mouse brains which limits their utility in murine PD models and eventual
translation in human clinical trials.8,9 Here we report that TAE684, a previously reported
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inhibitor of anaplastic lymphoma kinase (ALK),10 is also a potent LRRK2 inhibitor which
posses a favorable pharmacokinetic profile in mice.
In an effort to discover new compound classes that are capable of potently inhibiting
LRRK2 kinase activity and that also have the ability to traverse the blood–brain barrier
(BBB), we screened our in-house kinase targeted compound library using an LRRK2
enzymatic assay. TAE684, 5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-4-(4-
(4-methyl-piperazin-1-yl)piperidin-1-yl)phenyl)pyrimidine-2,4-diamine, a previously
reported ALK kinase inhibitor,10 emerged as a potent LRRK2 inhibitor with biochemical
IC50s of 7.8 and 6.1 nM against wild-type LRRK2 and LRRK2[G2019S], respectively (Fig.
1). While the biochemical potency of TAE684 for inhibition of wild-type and G2019S
LRRK2 is similar to LRRK2-IN-1, TAE684 maintains significant inhibition of the A2016T
mutation which induces dramatic resistance to LRRK2-IN-1 (Fig. 1). Although both
LRRK2-IN-1 and TAE684 share the aminopyrimidine pharmacophore, a molecular model
of TAE684 built based on a previously published crystallographic structure with ALK,11
suggests that isopropylsulfone moiety is able to avoid the steric clash that is likely between
the anthranilic acid ring of LRRK2-IN-1 with the A2016T residue (Fig. 2a,b).8,12,13 We next
examined the ability of TAE684 to inhibit LRRK2 in a cellular context in comparison to
LRRK2-IN-1. As there are no validated direct phosphorylation substrates of LRRK2, we
monitored phosphorylation of Ser910 and Ser935, two residues whose phosphorylation is
known to be dependent upon LRRK2 kinase activity14 (Fig. 3). TAE684 induced a dose-
dependent inhibition of Ser910 and Ser935 phosphorylation in both wild-type LRRK2 and
LRRK2[G2019S] stably transfected into HEK293 cells (Fig. 3a). Significant
dephosphorylation of Ser910 and Ser935 was observed at 0.1–0.3 µM of TAE684 for wild-
type LRRK2 and at slightly higher doses for LRRK2[G2019S] (Fig. 3a), which is
approximately 10-fold more potent compared to LRRK2-IN-1 (compare Fig. 3a to b).
Consistent with the biochemical results, TAE684 also induced dephosphorylation of Ser910
and 935 at a concentration of 1–3 µM in the drug-resistant LRRK2[A2016T+G2019S] and
LRRK2[A2016T] mutants (Fig. 3a), revealing that TAE684 has a different profile compared
to LRRK2-IN-1 (compare Fig. 3a to b).
We next examined the effect of TAE684 on endogenously expressed LRRK2 in human
lymphoblastoid cells derived from a control and Parkinson’s disease patient homozygous for
the LRRK2[G2019S] mutation (Fig. 4a). We found that increasing doses of TAE684 led to
similar dephosphorylation of endogenous LRRK2 at Ser910 and Ser935, as was observed in
HEK293 cells stably expressing wild-type LRRK2 or LRRK2[G2019S] (compare Figs. 3a
to 4a). Moreover, endogenous LRRK2 was also more sensitive to TAE684 than LRRK2-
IN-1, which is consistent with the trend we observed in HEK293 cells. We also found that
TAE684 induced similar dose-dependent Ser910 and Ser935 dephosphorylation of
endogenous LRRK2 in mouse Swiss 3T3 cells (Fig. 4b).
The mouse pharmacokinetic profile of TAE684 demonstrated excellent oral bioavailability
(83% F), half-life of 11.3 h and excellent plasma exposure (6374 h*ng/mL, AUClast) (Table
1). More importantly, TAE684 exhibited brain to plasma ratio of 2, indicating superior BBB
property (Table 1). Based on these excellent pharmacokinetic properties, pharmacodynamic
experiments examining inhibition of LRRK2 Ser910/Ser935 phosphorylation were
conducted after oral gavage administration with 10 mg/kg or 50 mg/kg of TAE684. We
observed complete Ser910 and Ser935 dephosphorylation of LRRK2 in the kidney and
spleen at dose of 50 mg/kg, and slightly lower effect at dose of 10 mg/kg. These also
demonstrated improved potency relative to LRRK2-IN-1 (Fig. 5).8 Unfortunately, despite
the significant exposure of TAE684 in the brain, no inhibition of LRRK2 Ser910 or Ser935
phosphorylation was observed in the brain (Fig. 5). We are currently investigating the
reasons for this unexpected result.
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The kinase selectivity of TAE684 was assessed using standard radioactivity-base enzymatic
assays against a panel of 124 kinases (Dundee profiling).15 At a concentration of 1 µM,
TAE684 inhibited the kinase activities of CAMKKβ, CHK2, FGF-1R, NUAK1,
PHKã1(PBK), and TSSK1 higher than 90% (detail results please see Supplementary data).
Recently published Kinomescan binding data against a panel of 442 kinases revealed that
TAE684 is a potent binder of many kinases with sub-100 nM Kds reported for: CAMKKβ,
CHK2, FGF-1R, NUAK1, PHKã1(PBK), and TSSK1.16 These results show that TAE684 is
a relatively broad-based kinase inhibitor and considerable less selective than LRRK2-IN-1
and CZC-25146.
In summary, we have discovered that TAE684 is a potent biochemical and cellular inhibitor
of LRRK2 kinase activity. Detailed characterization of TAE684 using LRRK2-IN-1 as a
bench mark revealed that TAE684 significantly inhibited phosphorylation of wild-type
LRRK2 and LRRK2[G2019S] mutant at Ser910 and Ser935 at 0.1–0.3 µM in vivo, which is
about 5–10-fold more potent than LRRK-IN-1. TAE684 is relatively insensitive to the
A2016T mutation which suggests that this mutant will not be useful to validate whether the
pharmacological effects of the compound are LRRK2-dependent. TAE684 achieves good
exposure to mouse brain following oral administration but interestingly does not inhibit
phosphorylation of Ser910 and Ser935 of LRRK2. Further characterization of clinical stage
kinase inhibitors related to TAE684 may result in the identification of other compounds that
might be relevant as pharmacological agents to investigate the impact of LRRK2 inhibition
in animal models and eventually in humans.
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Figure 1.
LRRK2 inhibitors.
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Figure 2.
Modeling study. (a) Molecular model of LRRK2-IN-1 with LRRK2[A2016]. Potential steric
clash is indicated. (b) Molecular model of TAE684 with LRRK2[A2016T]. Small molecules
are shown in space-filling mode and protein is depicted in ribbon format.
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Figure 3.
Compound TAE684 inhibits LRRK2 in cells. (a) HEK 293 cells stably expressing wild-type
GFP-LRRK2, GFP-LRRK2[G2019S], GFP-LRRK2[G2019S+A2016T], and GFP-
LRRK2[A2016T] were treated with DMSO or increasing concentrations of TAE684 for 90
min. Cell lysates were subjected to immunoblotting for detection of LRRK2 phosphorylated
at Ser910 and Ser935 and for total LRRK2. (b) As in (a) except LRRK2-IN-1 was used.
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Figure 4.
Compound TAE684 inhibits endogenously expressed LRRK2. (a) Endogenous LRRK2
from EBV immortalized human lymphoblastoid cells from a control subject and a
Parkinson’s disease patient homozygous for the LRRK2[G2019S] mutation. After treatment
of the cells with DMSO or the indicated concentration of TAE684 (or LRRK2-IN-1) for 90
min, cell lysates were subjected to immunoblot analysis with the purified indicated antibody
for western analysis. Immunoblots were performed in duplicate, and results were
representative of at least two independent experiments. (b) As in (a) except mouse Swiss
3T3 cells were used.
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Figure 5.
Pharmacodynamic analysis for TAE684. Pharmacodynamic study of TAE684 from brain,
spleen and kidney following oral administration at the indicated doses. Tissues were
collected and endogenous LRRK2 was resolved by SDS–PAGE and blotted with a phospho-
specific antibody directed against Ser910, Ser935 and total LRRK2.
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